Cargando…
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial
PURPOSE: This phase I, first in human, first in class clinical study aimed at evaluating the safety, tolerability and efficacy of treatment with genetically modified mesenchymal stromal cells (MSC) in combination with ganciclovir (GCV). MSC_apceth_101 are genetically modified autologous MSCs used as...
Autores principales: | von Einem, Jobst C., Peter, Sylvia, Günther, Christine, Volk, Hans-Dieter, Grütz, Gerald, Salat, Christoph, Stoetzer, Oliver, Nelson, Peter J., Michl, Marlies, Modest, Dominik P., Holch, Julian W., Angele, Martin, Bruns, Christiane, Niess, Hanno, Heinemann, Volker |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655186/ https://www.ncbi.nlm.nih.gov/pubmed/29113291 http://dx.doi.org/10.18632/oncotarget.20964 |
Ejemplares similares
-
Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial
por: Niess, Hanno, et al.
Publicado: (2015) -
Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials
por: Stahler, Arndt, et al.
Publicado: (2020) -
Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020) -
An inducible transgenic mouse breast cancer model for the analysis of tumor antigen specific CD8(+) T-cell responses
por: Bruns, Michael, et al.
Publicado: (2015) -
T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy
por: Bruns, Michael, et al.
Publicado: (2016)